NCT03425591View on ClinicalTrials.gov

A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice

CompletedOBSERVATIONAL

Enrollment

508

Participants

Timeline

Start Date

May 11, 2016

Primary Completion Date

August 11, 2022

Study Completion Date

August 11, 2022

Conditions

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-Cell

Interventions

DRUG

Ibrutinib

Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib in routine clinical practice settings will be observed for 5 years.

Trial Locations (1)

Unknown

Paris

All Listed Sponsors

lead

Janssen-Cilag Ltd.

INDUSTRY

NCT03425591 - A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice | Biotech Hunter | Biotech Hunter